A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

C. J. Twelves; U. Banerji; W. D. Tap; N. Cook; T. R. J. Evans; R. Plummer; A. Anthoney; C. Plummer; R. Dawson; P. Loadman; G. Lahu; H. Jones; N. Kinnersley; R. Edwards; G. Gordon; L. D. Cranmer

doi:10.1016/j.annonc.2024.08.712

A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

C. J. Twelves, U. Banerji, W. D. Tap, N. Cook, T. R. J. Evans, R. Plummer, A. Anthoney, C. Plummer, R. Dawson, P. Loadman, G. Lahu, H. Jones, N. Kinnersley, R. Edwards, G. Gordon, L. D. Cranmer

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S511-S511
Number of pages	1
Journal	Annals of Oncology
Volume	35
DOIs	https://doi.org/10.1016/j.annonc.2024.08.712
Publication status	Published - 1 Sept 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2024.08.712

Cite this

Twelves, C. J., Banerji, U., Tap, W. D., Cook, N., Evans, T. R. J., Plummer, R., Anthoney, A., Plummer, C., Dawson, R., Loadman, P., Lahu, G., Jones, H., Kinnersley, N., Edwards, R., Gordon, G., & Cranmer, L. D. (2024). A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors. Annals of Oncology, 35, S511-S511. https://doi.org/10.1016/j.annonc.2024.08.712

@article{d337640cd7634d58b37c5f8409cbac01,

title = "A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors",

author = "Twelves, {C. J.} and U. Banerji and Tap, {W. D.} and N. Cook and Evans, {T. R. J.} and R. Plummer and A. Anthoney and C. Plummer and R. Dawson and P. Loadman and G. Lahu and H. Jones and N. Kinnersley and R. Edwards and G. Gordon and Cranmer, {L. D.}",

year = "2024",

month = sep,

day = "1",

doi = "10.1016/j.annonc.2024.08.712",

language = "English",

volume = "35",

pages = "S511--S511",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

}

Twelves, CJ, Banerji, U, Tap, WD, Cook, N, Evans, TRJ, Plummer, R, Anthoney, A, Plummer, C, Dawson, R, Loadman, P, Lahu, G, Jones, H, Kinnersley, N, Edwards, R, Gordon, G & Cranmer, LD 2024, 'A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors', Annals of Oncology, vol. 35, pp. S511-S511. https://doi.org/10.1016/j.annonc.2024.08.712

A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors. / Twelves, C. J.; Banerji, U.; Tap, W. D. et al.
In: Annals of Oncology, Vol. 35, 01.09.2024, p. S511-S511.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

AU - Twelves, C. J.

AU - Banerji, U.

AU - Tap, W. D.

AU - Cook, N.

AU - Evans, T. R. J.

AU - Plummer, R.

AU - Anthoney, A.

AU - Plummer, C.

AU - Dawson, R.

AU - Loadman, P.

AU - Lahu, G.

AU - Jones, H.

AU - Kinnersley, N.

AU - Edwards, R.

AU - Gordon, G.

AU - Cranmer, L. D.

PY - 2024/9/1

Y1 - 2024/9/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001326612900639&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.annonc.2024.08.712

DO - 10.1016/j.annonc.2024.08.712

M3 - Meeting Abstract

SN - 0923-7534

VL - 35

SP - S511-S511

JO - Annals of Oncology

JF - Annals of Oncology

ER -

A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

UN SDGs

Access to Document

Other files and links

Cite this